Effect of Cerebrolysin in severe traumatic brain injury: A multi-center, retrospective cohort study

Lucena, Lynne Lourdes N; Briones, Marla Vina A

doi:10.1016/j.clineuro.2022.107216

Cited by 4 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 20 mL/day was the dosage for Muresanu et al, 2015 [ 22 ]. The most common dosage was 30 mL/day, administrated in the work of Alvarez et al in both 2003 and 2008 and by Chen et al, Lucena et al, and Muresanu et al in 2015 [ 22 , 23 , 24 , 25 , 26 ]. A total of 50 mL/day was administrated Poon et al, Wong et al, and Muresanu et al in 2020 [ 14 , 15 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

“…Our meta-analysis compares the treatment result among the clinical studies found in Pub Med, Cinahl, Web Of Science, and Embase from database inception until 11th July 2022 describing the effect of Cerebrolysin on patients diagnosed with TBI. The studies included both prospective randomized studies [ 15 , 25 , 27 ] and observational or historical cohorts [ 20 , 21 , 22 , 23 , 26 ]. In most of the analyzed studies, the authors point out the heterogeneity of the groups and the lack of consensus regarding the dose of the drug and the duration of its use [ 15 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…The positive effect of Cerebrolysin has been proven in vitro (decrease in microglial activity, excitotoxicity, production of free radicals, increase in neuronal survival) and has also been demonstrated in vivo in animal studies [ 7 , 16 , 33 , 34 ], as well as in clinical studies [ 15 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. In particular, the role of modeling the immune response deserves attention.…”

Section: Discussionmentioning

confidence: 99%

“…Khalil et al in 2017 stated that Cerebrolysin treatment in patients with severe TBI is associated with increased Glasgow Outcome Scale Extended (GOSE) score and reduced mortality [ 20 ]. Lucena et al in 2022 in their work with severe TBI patients confirmed that Cerebrolysin has a beneficial influence on GCS, GOS, and LOS [ 26 ]. Ashgari et al in 2014 stated that GCS was significantly higher in treatment groups in comparison with control [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

TBI (traumatic brain injury) is one of the most common causes of deaths and failure to return to society according to the latest statistics. Cerebrolysin is a drug approved for use in patients diagnosed with TBI. It is a mixture of neuropeptides derived from purified porcine brain proteins and multiple experimental studies have proven its neuroprotective and neurorestorative properties both in vitro and in vivo. In our meta-analysis, we analyze the latest clinical study reports on the use of Cerebrolysin in patients with TBI. The authors searched the databases: Pub Med, Cinahl, Web Of Science, and Embase from database inception until 11th July 2022. Ten clinical studies were eligible and included in the final analysis, including both retrospective and prospective studies of 8749 patients. Treatment with Cerebrolysin was associated with a statistically significant change in GCS and GOS. Mortality of any cause and the length of stay was not affected by the treatment. Our findings support and confirm the beneficial effects of Cerebrolysin treatment on the clinical outcome of patients after TBI. Further multi-center studies to optimize dosing and time of administration should be conducted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer’s Disease Exacerbated by Concussive Head Injury

Sharma

Mureșanu

Nozari

et al. 2023

Advances in Neurobiology

View full text Add to dashboard Cite

A Modern Approach to the Treatment of Traumatic Brain Injury

Syzdykbayev,

Kazymov,

Aubakirov

et al. 2024

Medicines

View full text Add to dashboard Cite

Background: Traumatic brain injury manifests itself in various forms, ranging from mild impairment of consciousness to severe coma and death. Traumatic brain injury remains one of the leading causes of morbidity and mortality. Currently, there is no therapy to reverse the effects associated with traumatic brain injury. New neuroprotective treatments for severe traumatic brain injury have not achieved significant clinical success. Methods: A literature review was performed to summarize the recent interdisciplinary findings on management of traumatic brain injury from both clinical and experimental perspective. Results: In the present review, we discuss the concepts of traditional and new approaches to treatment of traumatic brain injury. The recent development of different drug delivery approaches to the central nervous system is also discussed. Conclusions: The management of traumatic brain injury could be aimed either at the pathological mechanisms initiating the secondary brain injury or alleviating the symptoms accompanying the injury. In many cases, however, the treatment should be complex and include a variety of medical interventions and combination therapy.

show abstract

Effect of Cerebrolysin in severe traumatic brain injury: A multi-center, retrospective cohort study

Cited by 4 publications

References 35 publications

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis

Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer’s Disease Exacerbated by Concussive Head Injury

A Modern Approach to the Treatment of Traumatic Brain Injury

Contact Info

Product

Resources

About